A funded expert second opinion for every new high-stakes or rare cancer diagnosis
Anyone diagnosed with a rare or complex cancer gets an automatic remote review by a specialist centre, paid for by the health system, before treatment starts.
Second opinions change diagnosis or management in a substantial minority of rare cancer cases (sarcoma, lymphoma subtyping, neuroendocrine tumours) and pathology discordance for rare tumours is well documented. Reference-centre networks (French NETSARC, EURACAN) show the model. The proposal is an entitlement to a remote expert review, delivered through virtual tumour boards, funded per case, with turnaround within 10 working days and the report returned to both the local team and the patient in plain language.
- Patients lack understanding, navigation and agency · Most patients cannot understand their options, find trials, or push back, so decisions are made for them.
- Rare and paediatric cancers without markets · Taken together rare cancers are a fifth of all cancers, but each one alone is too small for a company to invest in.
Pages like this
not linked directly; found by shared links- IdeaMandatory national virtual tumour boards for rare and complex cancers
Shares Neuroendocrine tumours, Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- CompanySpringWorks Therapeutics (Merck KGaA)
Shares Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- IdeaTrial-in-a-box: a preconfigured protocol kit any hospital can open for a rare cancer
Shares Neuroendocrine tumours, Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- IdeaOne legal framework for pooling rare cancer data across borders
Shares Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- IdeaOne global rare cancer network with n-of-1 and Bayesian trial frameworks
Shares Neuroendocrine tumours, Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- IdeaLet adolescents from age 12 into adult trials when the cancer biology is the same
Shares Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- IdeaThe pathology lab triggers a trial referral the day a rare cancer is diagnosed
Shares Neuroendocrine tumours, Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- TermFNCLCC grade (soft-tissue sarcoma)
Shares Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).